Loading...
•
Mar 31, 2025
PetMed Express Q4 2025 Earnings Report
PetMed Express reported a quarterly net loss driven by declining revenue, increased impairment charges, and reduced customer acquisition.
Key Takeaways
PetMed Express faced a challenging Q4 2025, with revenue dropping 18.9% YoY and a net loss of $11.6 million. EPS came in at -$0.56, with adjusted EPS at -$0.25. The company cited macroeconomic pressure, reduced advertising spend, and customer acquisition softness as key factors impacting performance.
Revenue for Q4 fell to $47.7 million, down from $58.9 million in Q4 2024.
Net loss widened to $11.6 million, partly due to a $1.2 million impairment loss.
EPS was -$0.56, while adjusted EPS was -$0.25, reflecting ongoing cost pressures.
New customer acquisition dropped to 66,000 compared to 108,000 in the same period last year.
Revenue by Geographic Location
Forward Guidance
PetMed Express is executing a multi-channel transformation strategy with investments in private label launches, Amazon expansion, and technology upgrades, but macroeconomic pressures and customer acquisition challenges remain headwinds.
Positive Outlook
- Recurring sales remain strong, representing over 56% of gross sales.
- Strategic partnerships with Dutch and Mixlab to expand telehealth and compound pharmacy services.
- Private label product line expected to launch on Amazon in early FY2026.
- E-commerce modernization and omnichannel investments in progress.
- Improved operational controls following restatement and leadership changes.
Challenges Ahead
- Customer acquisition dropped 39% YoY in Q4.
- Revenue declined 18.9% YoY due to lower ad spend and macro headwinds.
- Higher discounting and promotions reduced gross margin.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...